Table 1.
Retrospective test sets
| Proprietary or code name | INN (Target) | Species | HSC score of original clone | Starting structure |
|---|---|---|---|---|
| Model vs. crystal structure | ||||
| CAMPATH-1G | CD52 | Rat | 82.87 | 1BFO |
| GNC92H2 | GNC | Chimeric | 81.69 | 1I7Z |
| Remicade | Infliximab (TNF) | Chimeric | 79.91 | 4G3Y |
| Simulect | Basiliximab (IL2RA) | Chimeric | 75.8 | 3IU3 |
| cT84.66 | CEACAM5 | Chimeric | 74.85 | 1J05 |
| Lazar et al.7 | ||||
| AC10 | CD30 | Chimeric | 79.66 | — |
| Erbitux (225) | Cetuximab (EGFR) | Chimeric | 75.23 | 1YY8 |
| Re-humanization | ||||
| CAMPATH-1H | Alemtuzumab (CD52) | Humanized | 82.87 | — |
| Avastin | Bevacizumab (VEGF-A) | Humanized | 77.31 | — |
| Herceptin | Trastuzumab (ERBB-2) | Humanized | 74.72 | — |